← #events

International blended course Clinical Development- PJ Futurelab

Van derden

07/10/19


The international blended course Clinical Development from Paul Janssen Futurelab Leiden (hereafter PJ Futurelab) is a highly rated course (4.4 out of 5 stars) that guides graduated biomedical professionals through the developmental process of new medical interventions and gives you guidance on the development of your first-in-man trial. PJ Futurelab is a non-profit, independent education & training initiative of the Leiden University Medical Centre (LUMC) and Leiden University. Our mission is to train graduated biomedical professional to be tomorrow’s leaders in life sciences.

Full scholarships for start-ups

Janssen Campus the Netherlands has kindly made available 2 scholarships for the complete blended course Clinical Development. Eligible candidates are graduated (bio)medical professionals working in an early phase start-up which has (as yet) no clinical development program, but have concrete plans to start a first-in-man trial within 1 – 1.5 years. The scholarship covers the full course fee of € 5600,- and gives access to the complete blended course which consists of 3 parts: a 5-week online introduction course + 4 days on-campus + 5 days on-campus extended.

 

Eligible candidates may apply for the scholarships via this form https://www.pauljanssenfuturelab.eu/about/scholarships-and-grants/scholarships-for-start-ups/ . The application deadline is October 3, 2019, 12:00 CET. All submitted information is treated confidentially. PJ Futurelab’s Selection Committee will select and inform the candidates after the application deadline.

 

The online course starts on  October 7, 2019. Participants who successfully complete the online course are invited to join the on-campus and on-campus extended courses. The on-campus course is held from June 8-12, 2020  at castle Oud Poelgeest, Oegstgeest, the Netherlands. The on-campus extended course is held from June 12-18, 2020 in Centre for Human Drug Research (CHDR), Leiden, the Netherlands.